drugset / Trial / NCT00970385
Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma
Phase 3
Completed
95 enrolled
University Hospital, Grenoble
French Innovative Leukemia Organisation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter randomized trial evaluating induction treatment with VIP-reinforced-ABVD (VIP-rABVD) versus CHOP/21 in patients with newly diagnosed peripheral T cell lymphoma.
Timeline
- Start
- 1995-01
- Primary completion
- 2002-12
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bleomycin | Unknown | 10 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | — |
| Comparator | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Subject | Dacarbazine | Small molecule | 375 mg/m2 | — |
| Comparator | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Ifosfamide | Small molecule | 1000 mg/m2 | — |
| Comparator | Prednisone | Other / unclassified | 100 mg/m2 | — |
| Subject | Vinblastine | Small molecule | 10 mg/m2 | — |
| Comparator | Vincristine | Small molecule | 1.4 mg/m2 | — |